As the companies have pointed out, though, they estimate only 1.6 million patients will qualify for Dupixent treatment under the indication U.S. regulators are currently reviewing, and that’s just a small piece of the much larger eczema pie.
Meanwhile, the partners are also eyeing indications in a variety of other allergy-related disorders, including asthma. As Sanofi CEO Olivier Brandicourt put it during a presentation at the J.P. Morgan Healthcare Conference in January, “Dupixent can be a pipeline, frankly, in itself.”
Now this sounds exciting if in Teneo touch- 1.6 million potential patients for eczema alone and a pipeline for other indications
UNS Price at posting:
3.5¢ Sentiment: Buy Disclosure: Held
